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Abstract: 
The psychoactive properties of lysergic acid diethylamide (LSD) have 
fascinated scientists across disciplines and the exploration of other analogs 
and derivatives has been motivated by deepening the understanding of 
ligand-receptor interactions at the molecular level as well as by the search 
for new therapeutics. Several LSD congeners have appeared on the new 
psychoactive substances (NPS) market in the form of blotters or powders. 
Examples include 1-propionyl-LSD (1P-LSD), AL-LAD and LSZ. The absence 
of analytical data for novel compounds is a frequent challenge encountered 
in clinical and toxicological investigations. Two newly emerging 
lysergamides N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1P-
ETH-LAD were characterized by gas chromatography mass spectrometry 
(GC-MS), low and high mass accuracy electrospray MS(/MS), GC solid-
state infrared analysis, high performance liquid chromatography diode 
array detection as well as nuclear magnetic resonance spectroscopy. 
Limited analytical data for ETH-LAD were previously available, whereas 
information about 1P-ETH-LAD has not previously been encountered in 
scientific literature. This study extends the characterization of lysergamides 
distributed on the NPS market, which will help to make analytical data 
available to clinicians, toxicologists and other stakeholders who are likely 
to encounter these substances. The analysis of a test incubation of 1P-ETH-
LAD with human serum at 37°C by LC single quadrupole MS at various 
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time points (0–6 h, once per hour and one measurement after 24 h) 
revealed the formation of ETH-LAD, suggesting that 1P-ETH-LAD might 
serve as a pro-drug. 1P-ETH-LAD was still detectable in serum after 24 h. 
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Abstract 
 
The psychoactive properties of lysergic acid diethylamide (LSD) have fascinated 
scientists across disciplines and the exploration of other analogs and derivatives has 
been motivated by deepening the understanding of ligand-receptor interactions at the 
molecular level as well as by the search for new therapeutics. Several LSD 
congeners have appeared on the new psychoactive substances (NPS) market in the 
form of blotters or powders. Examples include 1-propionyl-LSD (1P-LSD), AL-LAD 
and LSZ. The absence of analytical data for novel compounds is a frequent 
challenge encountered in clinical and toxicological investigations. Two newly 
emerging lysergamides N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1P-
ETH-LAD were characterized by gas chromatography mass spectrometry (GC-MS), 
low and high mass accuracy electrospray MS(/MS), GC solid-state infrared analysis, 
high performance liquid chromatography diode array detection as well as nuclear 
magnetic resonance spectroscopy. Limited analytical data for ETH-LAD were 
previously available, whereas information about 1P-ETH-LAD has not previously 
been encountered in scientific literature. This study extends the characterization of 
lysergamides distributed on the NPS market, which will help to make analytical data 
available to clinicians, toxicologists and other stakeholders who are likely to 
encounter these substances. The analysis of a test incubation of 1P-ETH-LAD with 
human serum at 37°C by LC single quadrupole MS at various time points (0–6 h, 
once per hour and one measurement after 24 h) revealed the formation of ETH-LAD, 
suggesting that 1P-ETH-LAD might serve as a pro-drug. 1P-ETH-LAD was still 
detectable in serum after 24 h. 
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Introduction 
 
Whereas the history of human use of psychoactive lysergamides goes back at least 
centuries with the ritual usage of ergine (d-lysergic acid amide),[1] the synthesis and 
psychoactive effects of lysergic acid diethylamide (LSD) have been described in the 
early 1940s.[2,3] Since that time, the pharmacological and psychoactive properties of 
LSD and its congeners have attracted substantial interest and one area of focus has 
been the structure-activity relationships of lysergic acid amides. For example, studies 
have examined the effect of alkyl substitution at the N6-position, which contains a 
methyl substituent in the case of LSD (Figure 1). Synthesis and pharmacological 
evaluation of a series of N6-alkyl norlysergic acid diethylamide derivatives revealed 
that LSD-like activity in rats was either maintained or increased with ethyl, n-propyl, 
or allyl substituents, whereas longer or bulkier substituents such as isopropyl and n-
butyl reduced activity.[4-6] The extent to which these findings are translatable to 
humans remains unclear but anecdotal reports indicate that some N6-alkyl 
homologues of LSD have hallucinogenic effects in humans.[7,8] From the perspective 
of molecular pharmacology, investigating the structure-activity relationships of 
lysergic acid amides may help to elucidate the molecular interactions that occur 
between LSD and its biological targets.[9-11]   
 
Currently, a wide variety of psychoactive substances are marketed to the general 
public by Internet vendors; most of these substances, commonly referred to as new 
psychoactive substances (NPS) or ‘research chemicals’, were originally synthesized 
during the course of legitimate scientific research, but some were developed by NPS 
vendors as potential recreational drugs.[12,13] To date, only a few LSD congeners 
have appeared on the NPS market. N6-Allyl-6-norlysergic acid diethylamide (AL-LAD) 
and (2’S,4’S)-lysergic acid 2,4-dimethylazetidide (LSZ), which have been available 
on the NPS market for a few years as bulk powdered material or absorbed on blotter 
paper,[14] are examples of compounds repurposed from the scientific literature.[4,15] 
Conversely, 1-propionyl-LSD (1P-LSD; Figure 1), which first appeared online in early 
2015, had never been described in the scientific literature prior to its appearance as 
a new psychoactive substance.[16]  
 
The preparation of N6-ethyl-6-norlysergic acid diethylamide ((8β)-N,N,6-triethyl-9,10-
didehydroergoline-8-carboxamide, ETH-LAD; Figure 1) was first reported in 1976.[17] 
The same group subsequently found that ETH-LAD mimics the hyperthermic effect of 
LSD in rabbits and rats[18] and has greater oxytocic activity than LSD in the isolated 
rat uterus.[19] ETH-LAD reportedly produces complete substitution in rats trained to 
discriminate LSD and is even more potent than the training drug.[4] In addition, ETH-
LAD was subsequently shown to produce hallucinogenic effects in humans at slightly 
lower doses compared with LSD,[7] which is consistent with the relative potencies of 
ETH-LAD and LSD in the drug discrimination paradigm. Moreover, similar to LSD, 
ETH-LAD has high affinity for 5-HT2A receptors (Ki = 5.1 nM vs. [
3H]ketanserin), 
dopamine D1 receptors (Ki = 22.1 nM vs. [
3H]SCH-23390), and dopamine D2 
receptors (Ki = 4.4 nM vs. [
3H]spiperone).[4,20] Both LSD and ETH-LAD were found to 
act as partial agonists (measured using cAMP accumulation) when tested in C-6 
glioma cells expressing the rhesus macaque D1A receptor.
[20] In contrast to ETH-LAD, 
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no information about 1-propionyl-ETH-LAD (1P-ETH-LAD; Figure 1) was found in the 
scientific literature.  
 
In the present study, the newly emerging lysergamides ETH-LAD and 1P-ETH-LAD 
were extensively characterized using a variety of chromatographic, mass 
spectrometric, and spectroscopic methods.  To date, only limited analytical data have 
been reported for ETH-LAD and information about 1P-ETH-LAD appears to be 
absent from the literature. These studies extend the characterization of lysergamides 
distributed on the NPS market,[14,16] which will help to make analytical data available 
to clinicians, toxicologists and other stakeholders who are likely to encounter these 
substances. Previous work on 1P-LSD indicated that it served as a pro-drug for LSD 
when incubated in human serum.[16] In the present study, a test incubation of 1P-
ETH-LAD with human serum at 37°C was also included to ETH-LAD formation. 
 
Experimental 
 
Materials 
 
All chemicals used were of analytical or HPLC grade and were obtained either from 
Rathburn Chemicals Ltd (Walkerburn, Scotland, UK), Fisher Scientific (Dublin, 
Ireland) or Aldrich (Dorset, UK). Dimethyl sulphoxide-d6 (99.9% D) was from Aldrich. 
Powdered samples of ETH-LAD and 1P-ETH-LAD were provided by Synex 
Synthetics BV (Delft, The Netherlands) and characterized as the hemitartrate salt 
forms.  
 
Instrumentation  
 
Gas chromatography mass spectrometry  
 
Electron ionization (EI) mass spectra (70 eV) were recorded using a Finnigan TSQ 
7000 triple stage quadrupole mass spectrometer coupled to a gas chromatograph 
(Trace GC Ultra, Thermo Electron, Dreieich, Germany). Sample introduction was 
carried out using a CTC CombiPAL (CTC Analytics, Zwingen, Switzerland) 
autosampler. The emission current was 200 µA and the scan time was 1 s spanning 
a scan range between m/z 29–m/z 600. The ion source temperature was maintained 
at 175°C. Samples were introduced via gas chromatography with splitless injection 
using a fused silica capillary DB-1 column (30 m × 0.25 mm, film thickness 0.25 µm). 
For the analysis of ETH-LAD, the temperature program consisted of an initial 
temperature of 80°C, held for 1 min, followed by a ramp to 280°C at 15°C/min. The 
final temperature was held for 21 min. For the analysis of 1P-ETH-LAD, the 
temperature program consisted of an initial temperature of 80°C, held for 2 min, 
followed by a ramp to 310°C at 20°C/min. The final temperature was held for 23 min. 
The injector temperature was 220°C/250°C (for ETH-LAD/1P-ETH-LAD, 
respectively). The transfer line temperature was maintained at 280°C/300°C (for 
ETH-LAD/1P-ETH-LAD, respectively) and the carrier gas was helium in constant flow 
mode at a flow rate of 1.2 mL/min. Approximately 2 mg were dissolved in 1.5 mL 
chloroform. For analysis, 1 µL sample solution was injected into the GC-MS system. 
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Kovats retention indices (RI) were calculated from measurement of an n-alkane 
mixture analyzed with the above-mentioned temperature programs. 
Gas chromatography solid-state infrared analysis 
 
Samples were analyzed using a GC-solid phase-IR-system that consisted of an 
Agilent GC 7890B (Waldbronn, Germany) with probe sampler Agilent G4567A and a 
DiscovIR-GC™ (Spectra Analysis, Marlborough, MA, USA). The column eluent was 
cryogenically accumulated on a spirally rotating ZnSe disk cooled by liquid nitrogen. 
IR spectra were recorded through the IR-transparent ZnSe disk using a nitrogen-
cooled MCT detector. GC parameters: injection in splitless mode with an injection 
port temperature set at 240°C and a DB-1 fused silica capillary column (30 m × 
0.32 mm i.d., 0.25 µm film thickness). The carrier gas was helium with a flow rate of 
2.5 mL/min and the oven temperature program was as follows: 80°C for 2 min, 
ramped to 290°C at 20°C/min, and held at for 20 min. The transfer line was heated at 
280°C. Infrared conditions: oven temperature, restrictor temperature, disc 
temperature, and Dewar cap temperatures were 280°C, 280°C, -40°C, and 35°C, 
respectively. The vacuum was 0.2 mTorr, disc speed 3 mm/s, spiral separation was 1 
mm, wavelength resolution 4 cm-1 and IR range 650–4000 cm-1. Acquisition time was 
0.6 s/file with 64 scans/spectrum. Data were processed using GRAMS/AI Ver. 9.1 
(Grams Spectroscopy Software Suite, Thermo Fischer Scientific, Dreieich, Germany) 
followed by implementation of the OMNIC Software, Ver. 7.4.127 (Thermo Electron 
Corporation, Dreieich, Germany). 
 
High mass accuracy electrospray mass spectrometry  
Ultrahigh-performance liquid chromatography quadrupole time-of-flight single and 
tandem mass spectrometry (UHPLC-QTOF-MS/MS) data were obtained from an 
Agilent 6540 UHD Accurate-Mass Q-TOF LC-MS system coupled to an Agilent 1290 
Infinity UHPLC system (Agilent, Cheshire, UK). Separation was achieved using an 
Agilent Zorbax Eclipse Plus C18 column (100 mm × 2.1 mm, 1.8 µm) (Agilent, 
Cheadle, UK). Mobile phases consisted of 100% acetonitrile (1% formic acid) and 
1% formic acid in water. The column temperature was set at 40°C (0.6 mL/min) and 
data were acquired for 5.5 min. The gradient was set at 5–70% acetonitrile over 3.5 
min, then increased to 95% acetonitrile in 1 min and held for 0.5 min before returning 
to 5% acetonitrile in 0.5 min. QTOF-MS data were acquired in positive mode 
scanning from m/z 100–m/z 1000 with and without auto MS/MS fragmentation. 
Ionization was achieved with an Agilent JetStream electrospray source and infused 
internal reference masses. QTOF-MS parameters: gas temperature 325°C, drying 
gas 10 L/min and sheath gas temperature 400 °C. Internal reference ions at m/z 
121.0509 and m/z 922.0098 were used for calibration purposes.   
 
Liquid chromatography electrospray ionization mass spectrometry 
 
HPLC single quadrupole mass spectrometry (LC-Q-MS) analyses were carried out 
on an Agilent 1100 system using a Restek (Bellefonte, PA, USA) Allure PFPP 
column (5 µm, 50 x 2.1 mm). The aqueous mobile phase A consisted of 0.1% formic 
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acid, whereas, mobile phase B consisted of 0.1% formic acid in acetonitrile. The total 
run time was 25 min. The following gradient elution program was used: 0–2 min 2% 
B, followed by an increase to 60% within 15 min, then up to 80% within 20 min, 
returning to 2% within 25 min. The Agilent LC-MSD settings were as follows: positive 
electrospray mode, capillary voltage 3500 V, drying gas (N2) 12 L/min at 350°C, 
nebulizer gas (N2) pressure 50 psi, scan mode m/z 70–m/z 500, fragmentor voltage 
values used for in-source collision-induced dissociation (CID) were 30 V and 150 V, 
respectively. The sample was dissolved in acetonitrile/water (1:1, containing 0.1% 
formic acid) at a concentration of 10 µg/mL. The injection volume was 1 µL, flow rate 
was 0.80 mL/min and the column temperature was 30°C.  
 
Nuclear magnetic resonance spectroscopy  
 
Samples were prepared in deuterated dimethyl sulfoxide (DMSO-d6). 
1H NMR 
spectra (400.23 MHz) were recorded on a Bruker Avance III 400 NMR spectrometer 
using  a  5mm  BBFO  probe  with  z gradients. 13C  spectra (150.90 MHz) were 
recorded on a Bruker AV600 NMR spectrometer using a 5 mm TCI cryoprobe. 
Spectra were referenced to residual solvent and assignments were supported by 
both 1D and 2D experiments.   
 
Results and discussion 
 
The EI mass spectra for ETH-LAD and 1P-ETH-LAD are shown in Figure 2 and it 
can be seen that the relative abundance of the molecular ions was significant for 
both compounds, which was in agreement with other lysergamides investigated 
previously.[14,16] Some key fragments recorded for ETH-LAD (Figure 2A) were 
reported previously;[17] additionally, the entire EI mass spectrum depicted here is 
identical to the spectrum of a purported ETH-LAD sample that was published in the 
public domain.[21] The majority of the ETH-LAD spectrum exhibited fragments that 
were also encountered in the mass spectrum of LSD, such as the iminium ions at 
m/z 72, fragment clusters at m/z 151–m/z 156, m/z 178–m/z 182 or m/z 205–m/z 208, 
and the retro-Diels-Alder fragment at m/z 280.[16] As suggested in the Supporting 
Information section, further fragmentation of this particular species might have 
accounted for the formation of both the m/z 265 and m/z 207 species, respectively. 
The same three ions were also observed in the EI mass spectra of LSD[16] and AL-
LAD[14], which were considered characteristic for lysergamides with N,N-diethylamide 
substitution given that the N6-alkyl group is lost during fragmentation, thus, not 
impacting on the masses of the resulting ions. Aside from the m/z of M+, the most 
prominent feature that pointed to ETH-LAD (i.e. reflecting the presence of the N6-
ethyl group) was detected at m/z 235, presumably induced via a loss of N,N-
diethylformamide and cleavage of a hydrogen radical (see the Supporting 
Information). Correspondingly, the equivalent species in LSD may have been 
observed at m/z 221 (N6-methyl),[16] whereas the N6-allyl equivalent in AL-LAD 
(Figure 1) would have given rise to m/z 247.[14] The EI mass spectrum recorded for 
1P-ETH-LAD (Figure 2B) was comparable to those recorded for LSD and 1P-LSD;[16]  
the two most important features differentiating the EI-MS of 1P-ETH-LAD and 1P-
LSD were the 14 Da (N6-ethyl group) mass shifts at the m/z 236–m/z 237 and m/z 
291–m/z 293 clusters. In the case of 1P-LSD, these shifts were detected at 221–m/z 
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223 and m/z 277–m/z 279.[16] The detection of m/z 336, m/z 321 and m/z 263 (Figure 
2B) represented the mass shift induced by the 1-propionyl group and might have 
reflected the retro-Diels Alder counterpart at m/z 280 followed by formation of m/z 
265 and m/z 207 mentioned above for N,N-diethylamides LSD and AL-LAD 
(Supporting Information). As described in the Experimental section, the GC analysis 
of 1P-ETH-LAD required higher temperatures in order to facilitate the determination 
of the Kovats retention index since the implementation of the temperature profile 
used to elute ETH-LAD resulted in a retention time beyond the last eluting alkane 
standard.  
 
When subjected to GC-MS analysis, ETH-LAD but not 1P-ETH-LAD formed three 
additional degradation products of comparatively minor abundance (see the 
Supporting Information); the similarity of the mass spectral data indicated that these 
GC-induced degradations (which were absent under HPLC conditions) might have 
reflected the presence of isomeric species. The EI mass spectrum shown in Figure 
2A belongs to the most abundant peak, which is referred to as isomer III (see the 
Supporting Information). GC-induced degradation was also observed previously in an 
investigation of LSZ, although degradation did not occur during the analysis of AL-
LAD.[14] The solid-state infrared (sIR) spectra recorded from the peaks eluting from 
the GC column, as well as those recorded directly from the hemitartrate salts, are 
provided as Supporting Information. The advantage of using GC-sIR is that also 
compound mixtures and substances available in small amounts, such as those 
encountered on blotters, are amenable to IR analysis. The resulting spectra are 
comparable to those obtained under traditional conditions where individual (and 
pure) substances are converted to the free base state and subjected to neat ATR-IR 
measurements. A key difference between ETH-LAD and 1P-ETH-LAD was the 
absence of the indole NH group in the latter (~3000 cm-1), which is comparable with 
observations made previously with 1P-LSD. Correspondingly, the appearance of a 
second carbonyl signal in the spectrum of 1P-ETH-LAD was detected at 1704 cm-1 
due to the presence of the propionyl group in the 1-position. GC-sIR spectra could be 
recorded for three of the four ETH-LAD isomers and are included individually in the 
Supporting Information section. In the case of GC-MS analysis of 1P-ETH-LAD 
(Figure 2B), a different temperature profile was employed (see Experimental section) 
to ensure that elution occurred within the associated series of n-alkane standards for 
the determination of a suitable retention index.  
 
Similar to what was observed during GC-MS analysis, both ETH-LAD and 1P-ETH-
LAD could be conveniently separated using three different liquid chromatography 
(LC) systems (see Figure 3 and the Supporting information). The electrospray 
ionization mass spectra, obtained for both compounds using time-of-flight tandem 
MS as well as single quadrupole MS with in-source collision-induced dissociation, 
are shown in Figure 3. A product ion characteristic for ETH-LAD and 1P-ETH-LAD, 
presumably due to the presence of the N6-ethyl substituent, was the appearance of 
m/z 237 (Figure 3, calculated m/z 237.1386) and m/z 293 (1P-ETH-LAD, calculated 
m/z 293.1648, Figure 3C), respectively. Proposed mechanisms of formation for ions 
formed under QTOF-MS/MS conditions (Figures 3A and 3C) are summarized in 
Figures 4 and 5. Potentially equivalent species observed with the N,N-diethylamides 
LSD and AL-LAD were detected at m/z 223 and m/z 249, respectively.[14,16] When 
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ETH-LAD and 1P-ETH-LAD were analyzed by LC single quadrupole MS in selected 
ion monitoring mode (inserts in Figures 3B and 3D), only one peak was observable, 
indicating that the iso-forms were not detectable under the conditions used, which 
provided support for the conclusion that the ETH-LAD isomers detected under GC-
MS conditions (see above) were artificially generated during analysis using this 
particular methodology. The LC-diode array detection data for both ETH-LAD and 
1P-ETH-LSD are shown as Supporting Information. The UV spectra were recorded 
from the HPLC peaks using a scan range between 200 nm and 595 nm and with 1P-
ETH-LAD it can be seen that the addition of the propionyl group to the indole 
nitrogen introduced a third significant peak, resulting in distinct peaks at 224.4, 253.5 
and 293.1 nm, compared to 226.0 and 310.5 nm for ETH-LAD (Supporting 
Information). For 1P-LSD, three distinct peaks were observed at 226, 250 and 294 
nm, compared with peaks at 222 and 314 nm for LSD, thus offering only limited 
opportunities to facilitate differentiation.[16] The analysis of a test incubation of 1P-
ETH-LAD with human serum at 37°C by LC single quadrupole MS at various time 
points (0–6 h, once per hour and one measurement after 24 h) revealed the 
formation of ETH-LAD, suggesting that 1P-ETH-LAD might serve as a pro-drug. 1P-
ETH-LAD, however, was still detectable in serum after 24 h (Supporting Information). 
This observation was in agreement with what was observed previously during the 
incubation of 1P-LSD, which hydrolyzed to LSD under comparable conditions.[16]  
 
The nuclear magnetic resonance spectroscopy (NMR) data collected for ETH-LAD 
and 1P-ETH-LAD are summarized in Tables 1 and 2; all spectra are supplied as 
Supporting Information. The suggested assignments were based on several 
lysergamides characterized previously (1P-LSD, LSD, AL-LAD and LSZ)[14,16] and 
with the help of 1D and 2D experiments. One key difference observed between ETH-
LAD and 1P-ETH-LAD is that an indole nitrogen proton resonance at 10.75 ppm was 
absent in the latter compound due to the propionyl group attachment to the 1-
position. Correspondingly, a second carbonyl signal appeared in the 13C NMR 
spectrum of 1P-ETH-LAD at 172.45 ppm. In comparison to ETH-LAD, the 1H NMR 
spectrum of 1P-ETH-LAD also revealed a noticeable downfield shift for the aromatic 
protons H-12, H-14 and H-2. For example, the H-2 proton of ETH-LAD, found to 
overlap with H-12 and H-13 at 7.11–6.98 ppm, was detected as a distinct fine doublet 
at 7.59 ppm (J = 1.8 Hz) in 1P-ETH-LAD (Tables 1 and 2). The remaining proton 
chemical shifts remained largely unaffected. However, the presence of the propionyl 
group in 1P-ETH-LAD also led to increasing signal overlap further upfield from the 
aromatic chemical shifts. For example, the methylene protons (H-25) were observed 
to overlap with one of the protons of the N6-CH2 group (H-17) integrating to three 
protons. The triplet associated with the propionyl methyl group (H-26) overlapped 
with one of the triplets corresponding to the methyl groups present in the N,N-
diethylamide functionality. Similarly, the methyl group of the N6-susbtituent (H-18) 
overlapped with the triplet associated with the more upfield triplet of the N,N-
diethylamide group. As was the case with other lysergamides, the axial and 
equatorial configurations of the H-7 and H-4 protons resulted in distinct proton 
chemical shifts.[14,16] The two methylene protons of the N6-CH2 group (H-17) also 
displayed individual chemical shift values for each proton (Tables 1 and 2). Some 1H 
NMR data for ETH-LAD freebase in CDCl3 were reported previously,
[4,17,22] although 
there were minor differences in some chemical shift values, presumably due to 
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differences in the solvents used (d6-DMSO vs. CDCl3) and the hemitartrate form 
investigated in the present study. Attachment of the propionyl group affected some of 
the 13C carbon chemical shifts recorded for ETH-LAD, with the most pronounced 
downfield shifts experienced by C-3 (109.17 to 116.11 ppm), C-12 (111.58 to 116.50 
ppm) and C-14 (110.39 to 114.72 ppm), respectively.   
 
1P-LSD was previously shown to hydrolyze to LSD when exposed to human serum. 
[16] As depicted in the Supporting Information, 1P-ETH-LAD conversion to ETH-LAD 
was also identified following incubation in human serum at 37°C and analysis by LC-
MS analysis in selective ion monitoring mode. The analysis was carried out at 
various time points (0–6 h, once per hour and one measurement after 24 h) and it 
was found that ETH-LAD was detectable at first internal at 1 h, which indicated that 
1P-ETH-LAD might also serve as a pro-drug in vivo. 1P-ETH-LAD was still 
detectable in serum after 24 h. 
 
Conclusion 
 
In the present study, ETH-LAD and 1P-ETH-LAD, two recently emerging 
lysergamides available on the NPS market, were subjected to a comprehensive 
analytical characterization, which revealed that the differentiation between the two 
was straightforward. These studies extend the characterization of lysergamides 
distributed on the NPS market, which will help to make analytical data available to 
clinicians, toxicologists and other stakeholders who are likely to encounter these 
substances. Further studies are warranted to determine whether 1P-ETH-LAD shows 
bioactivity independent from the hydrolysis product ETH-LAD, which was detected 
during the incubation of 1P-ETH-LAD with human serum at 37°C.  
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Figure captions 
 
Figure 1. Lysergide (LSD) and derivatives that appeared on the new psychoactive 
substances market. 
Figure 2. Electron ionization mass spectra of ETH-LAD (A) and 1P-ETH-LAD (B). 
Figure 3. Electrospray ionization mass spectra. A and C: Quadrupole time-of-flight 
tandem mass spectra obtained from ETH-LAD and 1P-ETH-LAD. B and D: Single 
quadrupole mass spectra of ETH-LAD and 1P-ETH-LAD following in-source collision-
induced-dissociation. Inserts in B and D: HPLC single ion monitoring using the m/z 
values of the protonated molecules. 
 
Figure 4. Proposed formation of product ions following collision-induced dissociation 
of ETH-LAD under QTOF-MS/MS conditions. 
 
Figure 5. Proposed formation of product ions following collision-induced dissociation 
of 1P-ETH-LAD under QTOF-MS/MS conditions. 
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Lysergide (LSD) and derivatives that appeared on the new psychoactive substances market.  
Figure 1  
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Electron ionization mass spectra of ETH-LAD (A) and 1P-ETH-LAD (B).  
Figure 2  
283x413mm (300 x 300 DPI)  
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Electrospray ionization mass spectra. A and C: Quadrupole time-of-flight tandem mass spectra obtained 
from ETH-LAD and 1P-ETH-LAD. B and D: Single quadrupole mass spectra of ETH-LAD and 1P-ETH-LAD 
following in-source collision-induced-dissociation. Inserts in B and D: HPLC single ion monitoring using the 
m/z values of the protonated molecules.  
Figure 3  
292x419mm (300 x 300 DPI)  
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Figure 4. Proposed formation of product ions following collision-induced dissociation of ETH-LAD under 
QTOF-MS/MS conditions.  
Figure 4  
275x369mm (300 x 300 DPI)  
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Proposed formation of product ions following collision-induced dissociation of 1P-ETH-LAD under QTOF-
MS/MS conditions.  
Figure 5  
291x519mm (300 x 300 DPI)  
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Table 1. 
1
H and 
13
C NMR data for ETH-LAD hemitartrate in d6-
DMSO at 400 / 150 MHz 
 
No. 
13
C [δ / ppm] 
1
H [δ / ppm] 
1 – 10.75 (s, 1H) 
2 119.88 7.05 (t,  J = 2.0 Hz, 1H) 
a
 
3 109.17 – 
4 26.88 3.54–3.47 (m, 4β -H, 1H) 
b
 
2.60–2.51 (m, 4α-H, 1H) 
c
 
5 59.59 3.47–3.41 (m, H-5β, 1H) 
d
 
6 – – 
7 51.44 3.11 (dd, J = 10.8, 4.6 Hz, H-7α) 
e
 
2.84–2.67 (m, H-7β, 1H) 
f
 
8 39.22 3.83–3.71 (m, H-8α, 1H) 
9 120.64 6.24 (s, 1H) 
10 135.88 – 
11 127.85 – 
12 111.58 7.02 (dd,  J = 7.2, 0.8 Hz, 1H) 
g
 
13 122.79 7.07 (t,  J = 7.3 Hz, 1H) 
h
 
14 110.39 7.20 (dd, J = 7.2, 0.8 Hz, 1H) 
15 134.28 – 
16 126.31 – 
17 47.62 
47.62 
3.09–3.01 (m, 1H) 
i 
2.84–2.67 (m, 1H) 
j
 
18 10.37 1.09 (t, J = 7.2 Hz, 1H) 
k
 
19 171.09 – 
20 – – 
21 42.01 3.47–3.41 (m, 2H) 
l
 
21 39.72 3.32 (q, J = 7.1 Hz, 2H) 
22 15.29 1.19 (t, J = 7.1 Hz, 3H) 
22 13.55 1.07 (t, J = 7.1 Hz, 1H) 
m
 
TA 
n
 72.33 4.18 (s, 1H) 
TA
 n
 173.89 – 
 
a
 Overlapping with H-13 and H-12 
 
b 
Overlapping with H-5β and H-21 (2H) 
 
c 
Overlapping with solvent 
 
d 
Overlapping H-4β and H-21 (2H) 
 
e 
Overlapping H-17 (1H)  
 
f 
Overlapping with H-17 (1H) 
 
g
 Overlapping with H-13 and H-2 
 
1
2
3
4
15
14
13
12
5
7
8
9
10
11
16
NH
O
N
22
19
21
H
H
H
H
Hα α
β
α
β
21
22
20
6
17
18
Hβ
N
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h
 Overlapping with H-12 and H-2
 
 
i 
Overlapping with H-7α  
 
 
 
j 
Overlapping with H-7β 
 
k
 Overlapping with H-22 (3H) 
 
l 
Overlapping H-5β and H-4β (1H) 
 
m
 Overlapping with H-18 (3H) 
 
n 
TA: tartaric acid 
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Table 2. 1H and 13C NMR data for 1P-ETH-LAD hemitartrate in d6-
DMSO at 400 / 150 MHz 
 
No. 13C [δ / ppm] 1H [δ / ppm] 
1 – – 
2 119.89 7.59 (d, J = 1.8 Hz, 1H) 
3 116.11 – 
4 26.08 3.49 (dd, J = 15.3, 5.4 Hz, 4β-H, 1H) a 
2.49–2.39 (m, 4α-H, 1H) b 
5 58.23 3.41–3.36 (m, H-5β, 1H) c 
6 – – 
7 50.83 3.08 (dd, J = 11.4, 4.6 Hz, H-7α, 1H) d 
2.68–2.59 (m H-7β, 1H) e 
8 39.07 3.80–3.70 (m, H-8α, 1H) 
9 122.17 6.34 (s, 1H) 
10 134.05 – 
11 128.14 – 
12 116.50 7.34 (dd,  J = 7.6, 1.4 Hz, 1H) f 
13 125.86 7.31 (t,  J = 7.2 Hz, 1H) g 
14 114.72 8.01 (dd, J = 7.2, 0.8 Hz, 1H) 
15 133.08 – 
16 127.56 – 
17 46.94 
46.94 
3.37–3.26 (m, 1H) h 
2.77–2.68 (m, 1H) i 
18 9.99 1.07 (t, J = 7.0 Hz, 3H) j 
19 170.51 – 
20 – – 
21 41.54 3.47–3.41 (m, 2H) k 
21 39.43 3.37–3.26 (m, 2H) l 
22 14.79 1.19 (t, J = 7.0 Hz, 3H) m 
22 13.04 1.07 (t, J = 7.0 Hz, 3H) n 
23 172.45 – 
24 – – 
25 28.15 3.37–3.26 (m, 1H) o 
26 8.54 1.18 (t, J = 7.2 Hz, 3H) p 
TA q 71.94 4.25 (s, 1H) 
TA q 173.19 – 
 
a Overlapping with H-21 (2H) 
 
b Overlapping with solvent 
 
c Overlapping H-21 (2H) 
 
d Overlapping H-17 (1H) and H-25 
2
3
4
15
14
13
12
5
78
9
10
11
16
O
N22 19
21
H
H
H
H
Hα α
β
α
β21
22
20
6
17
18
Hβ
N
1N
O
23
25
2624
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e Overlapping with H-17 (1H) 
 
f
 Overlapping with H-13 
 
g
 Overlapping with H-12 
 
h Overlapping with H-7α and H-25   
 
i Overlapping with H-7β 
 
j
 Overlapping with H-22 (3H) 
 
k Overlapping H-4β (1H) 
 
l Overlapping H-5β (1H) 
 
m
 Overlapping with H-26 (3H) 
 
n Overlapping with H-18 (3H) 
 
o Overlapping with  H-7α and H-17 (1H) 
 
p Overlapping with H-22 (3H) 
 
o TA: tartaric acid 
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